<DOC>
	<DOCNO>NCT00062101</DOCNO>
	<brief_summary>This phase II trial study well give erlotinib together celecoxib work treat patient recurrent stage IIIB stage IV non-small cell lung cancer . Erlotinib celecoxib may stop growth tumor cell block enzymes necessary tumor cell growth . Celecoxib may slow growth tumor stop blood flow tumor . Combining erlotinib celecoxib may kill tumor cell .</brief_summary>
	<brief_title>Erlotinib Celecoxib Treating Patients With Stage IIIB Stage IV Recurrent Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine response rate patient stage IIIB IV recurrent non-small cell lung cancer treat erlotinib celecoxib second-line therapy . SECONDARY OBJECTIVES : I . Determine time progression patient treat regimen . II . Determine survival duration patient treat regimen . III . Determine toxicity regimen patient . IV . Correlate expression epidermal growth factor receptor cyclooxygenase-2 tumor specimen response , time progression , survival patient treat regimen . OUTLINE : Patients assign 1 2 treatment group . Group 1 : Patients receive oral erlotinib daily oral celecoxib twice daily . Group 2 : Patients receive erlotinib group 1 . Treatment group continue absence disease progression unacceptable toxicity . Patients follow every 2 month . PROJECTED ACCRUAL : A total 40-80 patient accrue study within 10 month .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>Histologically cytologically confirm nonsmall cell lung cancer Stage IIIB ( malignant pleural effusion ) IV Recurrent disease progress 1 2 prior chemotherapy regimen ( platinum nonplatinumbased ) At least 1 unidimensionally measurable lesion* At least 20 mm conventional technique OR least 10 mm spiral CT scan Must tissue specimen available assay No brain metastases Performance status ECOG 02 Performance status Karnofsky 60100 % More 3 month WBC least 3,000/mm^3 Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Bilirubin normal AST/ALT great 2.5 time upper normal limit ( ULN ) Creatinine normal Creatinine clearance least 60 mL/min No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia No prior abnormality cornea ( e.g. , dry eye syndrome Sj√∂gren 's syndrome ) No congenital abnormality ( e.g. , Fuch 's dystrophy ) No abnormal slitlamp examination use vital dye ( e.g. , fluorescein BengalRose ) No abnormal corneal sensitivity test ( e.g. , Schirmer test similar tear production test ) Able ingest oral medication No requirement IV alimentation No history peptic ulcer disease No active gastrointestinal ulcer Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No concurrent uncontrolled illness No ongoing active infection No significant traumatic injury within past 21 day No psychiatric illness social situation would preclude study compliance No prior allergic reaction sulfonamide , aspirin , nonsteroidal antiinflammatory drug No prior monoclonal antibody epidermal growth factor receptor ( EGFR ) More 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) recover No concurrent chemotherapy No concurrent glucocorticoid More 4 week since prior radiotherapy recover More 21 day since prior major surgery No prior surgery affect absorption No prior EGFRspecific tyrosine kinases No concurrent anticonvulsants No concurrent investigational agent No concurrent antiretroviral therapy HIVpositive patient No concurrent antacids No concurrent administration follow drug : Amiodarone Chloramphenicol Cimetidine Fluvoxamine Omeprazole Zafirlukast Clopidogrel Cotrimoxazole Disulfiram Fluconazole Fluoxetine Fluvastatin Fluvoxamine Isoniazid Itraconazole Ketoconazole Leflunomide Metronidazole Modafinil Paroxetine Phenylbutazone Sertraline Ticlopidine Valproic acid</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>